The FDA-cleared device targets osteopenia with a prescription approach as funding is directed toward expanding access, research and commercialization.
Osteobost Health seeks to turn the tide on a permanent blind spot in women’s health. The company just closed an $8 million round to scale up manufacturing and research for FDA-cleared wearables, a move that represents more than just an injection of capital; this is a push to finally make osteopenia something more than a “wait and see” diagnosis.
For the 10 million Americans with osteoporosis and the other 44 million with low bone density, the current pool is too low (1). The standard of care is notoriously manual, leaving millions of people with some form of diagnosis while they wait for their condition to worsen. Osteoboost attempts to fill this gap with a device that sits on the lower back and delivers calibrated vibration therapy to the spine. It also seems to be gaining ground; With clinical data showing a reduction in bone density and more than 2,500 doctors already prescribing it, the company removed the regulatory barrier and is now focused on something more difficult: convincing the health care system to pay attention.
Long life. Technology: If Osteoboost FDA clearance Suggesting that bone health has moved beyond the aesthetic blind spot of medicine, this rise raises the next question: could prevention be more of a strict advice and a way of calcium supplementation? The company sits in an interesting, commercially awkward space between consumer wearables and clinical interventions.
Osteopenia has long occupied a therapeutic ground. It’s serious enough to indicate a risk of future breakdown, but not enough to warrant drug therapy and channel it into good intentions. Osteoboost’s prescription model counters this inertia not by promising a miracle, but by offering a regulated effort to act early, when biology is still negotiable. This is noticeable. The fact that this applies to women’s health – an area often discussed with hopeful solemnity, but funded with less enthusiasm. The more difficult question now is not whether to convince clinicians, but whether payers will follow; Prevention is praised in theory, then seen as an added bonus in practice. If longevity is critical to maintaining mobility, such interventions may be less peripheral than they first appear. We sat down with Osteoboost CEO Laura Yesis to find out more.
Between health and medicine
The placement of Osteoboost is intentional. “Right now, when a woman is diagnosed with osteopenia, the standard advice is basically, ‘Exercise more and get more calcium,'” says Yesis. It’s a waiting and limbo game.”
This clinical strain goes beyond bone health. Osteopenia is measurable and predictable, but there is no definite cure. “That’s where we fit in,” Yesis continues. “Our device is established; it’s FDA cleared, it’s clinically tested, and it’s not a health gadget.”
By following the FDA Class II De Novo pathway, the company has overcome the “health” label to establish true efficacy. “Our goal is that physicians see it the way they see other carefully reviewed prescription therapies,” says Yesis, “a legitimate, evidence-based intervention without the risk of serious adverse drug-related events.”
From proxy to outcome
Clinical data focuses on bone density—a proxy for fracture risk. But as Yesi acknowledges, the bottom line that matters is life experience. “What matters is whether someone breaks their hip at age 78,” he says. “Hip fracture is devastating; the death toll is horrendous and the cost to the health care system is enormous.”
This shift—from a surrogate marker to an actual outcome—reflects a recalibration in longevity science, prioritizing functional independence over isolated biological metrics. The company is now gathering real data to back up its argument. “We’re collecting real-world results with patient consent,” Yesis notes, “and the case for payers is simple: paying for this upfront is cheaper than treating a late fracture.”
Design for compliance
Preventative tools live or die by user behavior. The Osteoboost regimen — 30-minute sessions, three times a week — isn’t difficult, but it’s not trivial. “The practice is designed to fit seamlessly into the patient’s daily life,” Yesis says. “They can wear it as they go about their day.”
Patterns emerge. “Patients who stick with it find a routine — whether it’s walking the dog or using a standing desk,” he says. The company reports an 82% compliance rate in clinical trials (2). “For patients who understand their risk and have a doctor who thinks it’s important, there’s more motivation.”
Capital, context and limitation
The $8 million collection comes on uneven ground. Women’s health attracts a fraction of healthcare investment, and funding is allocated to reproductive or oncology (3). Devices are at another disadvantage as capital flows toward software and AI.
Yecies is candid about the trip. “Eight years and a lot of persistence,” he says. “AI is taking up almost all of the oxygen in the business right now, and women’s health has never been the easiest fundraiser.”
However, the dynamics of the market are hard to ignore. “It’s a huge, underserved market, not a niche,” he says. Scale requires more than capital. “We need insurance to cover it,” he says. “Currently, patients pay out of pocket, which limits access.”
There is also a deep research gap here. “We need more research to focus on women from the start,” she adds. “And we need women to advocate for themselves. Many of us accept frailty as a natural part of aging — I see frailty as something important and entirely possible to work to avoid.”
The time between diagnosis and deterioration is long and inactive. Measures like Osteoboost suggest that this middle ground may be less fixed than once assumed — room not only for observation, but for action. Not dramatic. Not sure. But maybe enough.
Photo courtesy of Osteoboost
(1) https://www.bonehealthandosteoporosis.org/wp-content/uploads/Osteoporosis-Fast-Facts-2.pdf
(2) https://www.osteoboost.com/osteoboost-clinical-trial
(3) https://www.weforum.org/stories/2026/01/women-health-investment-outlook-mapping-opportunity-mobilizing-investment/
